3 results
In this study we want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by the EGFR tyrosine kinase inhibitor erlotinb and metformin, combined with gemcitabine in patients with metatastatic pancreatic…
Primary objective: Determine whether treatment with a PI3K inhibitor (BYL719 or buparlisib) plus letrozole leads to an increase in pathologic response compared to treatment with placebo plus letrozole in patients with hormone receptor-positive HER2-…
Primary objectives:- to assess the safety and tolerability of a single ascending intravenous (IV) infusion doses of the research medication.- to determine the maximum tolerated dose (MTD) of IV infusion doses of the research medication.Secundary…